Compare Eli Lilly And Co (LLY) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Eli Lilly And Co trades at $1,141 (market cap $1.02T), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $116.7. The key difference: Eli Lilly And Co pays a 0.6% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals.
| LLY | QQQE | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.24K | $122.72 |
52-Week Low | $625.65 | $96.06 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
QQQE trades at $116.70, down 0.09% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap-weighted peers. Recent news highlights its defensive appeal amid market shifts, with SpaceX's imminent Nasdaq-100 inclusion potentially driving passive inflows.
The outlook balances diversification benefits against market volatility risks. Equal weighting provides stability if mega-cap tech underperforms, but the bearish technical trend and neutral oscillators suggest near-term caution. Investors seeking Nasdaq exposure with lower single-stock risk may find QQQE attractive, though monitoring index rebalancing impacts is crucial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
